Back to top
more

Becton, Dickinson and Company (BDX)

(Delayed Data from NYSE)

$237.17 USD

237.17
674,442

-0.29 (-0.12%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $237.10 -0.07 (-0.03%) 5:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (176 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Labcorp (LH) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 2.14%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Conmed (CNMD) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 8.43% and 1.12%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk

by Zacks Equity Research

Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Apple, Amgen & Becton, Dickinson

by Sheraz Mian

Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Amgen Inc. (AMGN) and Becton, Dickinson and Company (BDX).

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

BD's (BDX) Tie-Up to Explore Flow Cytometry for Clinical Outcomes

by Zacks Equity Research

BD's (BDX) latest partnership is likely to accelerate the delivery of innovative personalized therapies to patients who need them the most.

AMN Healthcare (AMN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q2 performance.

DaVita (DVA) Tops Q2 Earnings Estimates, Ups FY23 EPS View

by Zacks Equity Research

DaVita's (DVA) robust dialysis patient service drives its second-quarter performance.

BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.

Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Becton Dickinson (BDX) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Becton Dickinson (BDX) delivered earnings and revenue surprises of 2.42% and 1%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for BD (BDX) This Earnings Season?

by Zacks Equity Research

BD (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

AmerisourceBergen (ABC) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

AmerisourceBergen (ABC) delivered earnings and revenue surprises of 3.18% and 5.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

DaVita (DVA) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) second quarter's top line.

Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter 2023 results are likely to reflect recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Debanjana Dey headshot

MedTech Stocks to Watch for Earnings on Aug 1: ECL, NVRO, INSP

by Debanjana Dey

MedTech companies' Q2 results are likely to reflect strength in customer demand. Let's see how ECL, NVRO and INSP are placed ahead of their earnings releases.

Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Revvity's (RVTY) second-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

McKesson (MCK) to Report Q1 Earnings: Is a Beat in Store?

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q3 sales.

Labcorp (LH) Q2 Earnings Lag Estimates

by Zacks Equity Research

Labcorp (LH) delivered earnings and revenue surprises of -1.44% and 1.62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.

Lantheus (LNTH) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Lantheus' (LNTH) second-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

Why Becton Dickinson (BDX) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Becton Dickinson (BDX) Surges 5.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Becton Dickinson (BDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.